These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 10565996)

  • 41. New goals to be achieved in clinical transplantation.
    Manez R
    Drug News Perspect; 2006 Oct; 19(8):509-12. PubMed ID: 17160153
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Phase I evaluation of ISIS 3521, an antisense oligodeoxynucleotide to protein kinase C-alpha, in patients with advanced cancer.
    Nemunaitis J; Holmlund JT; Kraynak M; Richards D; Bruce J; Ognoskie N; Kwoh TJ; Geary R; Dorr A; Von Hoff D; Eckhardt SG
    J Clin Oncol; 1999 Nov; 17(11):3586-95. PubMed ID: 10550158
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Biodistribution, stability, and antiviral efficacy of liposome-entrapped phosphorothioate antisense oligodeoxynucleotides in ducks for the treatment of chronic duck hepatitis B virus infection.
    Soni PN; Brown D; Saffie R; Savage K; Moore D; Gregoriadis G; Dusheiko GM
    Hepatology; 1998 Nov; 28(5):1402-10. PubMed ID: 9794928
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The clinical experience of antisense therapy to ICAM-1 in Crohn's disease.
    Yacyshyn B; Bowen-Yacyshyn MB; Shanahan W
    Curr Opin Mol Ther; 1999 Jun; 1(3):332-5. PubMed ID: 11713798
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Evidence of enhanced iron excretion during systemic phosphorothioate oligodeoxynucleotide treatment.
    Mata JE; Bishop MR; Tarantolo SR; Angel CR; Swanson SA; Iversen PL
    J Toxicol Clin Toxicol; 2000; 38(4):383-7. PubMed ID: 10930054
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Correlation of toxicity and pharmacokinetic properties of a phosphorothioate oligonucleotide designed to inhibit ICAM-1.
    Henry SP; Templin MV; Gillett N; Rojko J; Levin AA
    Toxicol Pathol; 1999; 27(1):95-100. PubMed ID: 10367680
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A randomized phase II and pharmacokinetic study of the antisense oligonucleotides ISIS 3521 and ISIS 5132 in patients with hormone-refractory prostate cancer.
    Tolcher AW; Reyno L; Venner PM; Ernst SD; Moore M; Geary RS; Chi K; Hall S; Walsh W; Dorr A; Eisenhauer E
    Clin Cancer Res; 2002 Aug; 8(8):2530-5. PubMed ID: 12171880
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Phase I safety and pharmacokinetic profile of an intercellular adhesion molecule-1 antisense oligodeoxynucleotide (ISIS 2302).
    Glover JM; Leeds JM; Mant TG; Amin D; Kisner DL; Zuckerman JE; Geary RS; Levin AA; Shanahan WR
    J Pharmacol Exp Ther; 1997 Sep; 282(3):1173-80. PubMed ID: 9316823
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Crohn's trial shows the pros of antisense.
    Robertson D
    Nat Biotechnol; 1997 Mar; 15(3):209. PubMed ID: 9062911
    [No Abstract]   [Full Text] [Related]  

  • 50. Modulation of plasma protein binding and in vivo liver cell uptake of phosphorothioate oligodeoxynucleotides by cholesterol conjugation.
    Bijsterbosch MK; Rump ET; De Vrueh RL; Dorland R; van Veghel R; Tivel KL; Biessen EA; van Berkel TJ; Manoharan M
    Nucleic Acids Res; 2000 Jul; 28(14):2717-25. PubMed ID: 10908328
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Development of antisense oligodeoxynucleotides for transplantation.
    Stepkowski SM
    Curr Opin Mol Ther; 2000 Jun; 2(3):304-17. PubMed ID: 11249625
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A randomised, controlled, double blind, escalating dose study of alicaforsen enema in active ulcerative colitis.
    van Deventer SJ; Tami JA; Wedel MK
    Gut; 2004 Nov; 53(11):1646-51. PubMed ID: 15479686
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Toxicity and toxicokinetics of a phosphorothioate oligonucleotide against the c-myc oncogene in cynomolgus monkeys.
    Webb MS; Tortora N; Cremese M; Kozlowska H; Blaquiere M; Devine DV; Kornbrust DJ
    Antisense Nucleic Acid Drug Dev; 2001 Jun; 11(3):155-63. PubMed ID: 11446591
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Technology evaluation: ISIS-3521.
    Li K; Zhang J; Sirois P; Hu Y
    Curr Opin Mol Ther; 1999 Jun; 1(3):393-8. PubMed ID: 11713804
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A randomized, double-masked, placebo-controlled study of alicaforsen, an antisense inhibitor of intercellular adhesion molecule 1, for the treatment of subjects with active Crohn's disease.
    Yacyshyn B; Chey WY; Wedel MK; Yu RZ; Paul D; Chuang E
    Clin Gastroenterol Hepatol; 2007 Feb; 5(2):215-20. PubMed ID: 17296530
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Drug treatment for Crohn's disease.
    Yacyshyn BR
    Lancet; 1998 Aug; 352(9129):743. PubMed ID: 9729027
    [No Abstract]   [Full Text] [Related]  

  • 57. Tresperimus. LF 080299.
    Drugs R D; 1999 Jan; 1(1):110-1. PubMed ID: 10566003
    [No Abstract]   [Full Text] [Related]  

  • 58. Intracellular distribution of digoxigenin-labeled phosphorothioate oligonucleotides.
    Tarrasón G; Bellido D; Eritja R; Vilaró S; Piulats J
    Methods Enzymol; 2000; 313():257-68. PubMed ID: 10595360
    [No Abstract]   [Full Text] [Related]  

  • 59. Pharmacokinetics and tolerability of intravenous trecovirsen (GEM 91), an antisense phosphorothioate oligonucleotide, in HIV-positive subjects.
    Séréni D; Tubiana R; Lascoux C; Katlama C; Taulera O; Bourque A; Cohen A; Dvorchik B; Martin RR; Tournerie C; Gouyette A; Schechter PJ
    J Clin Pharmacol; 1999 Jan; 39(1):47-54. PubMed ID: 9987700
    [TBL] [Abstract][Full Text] [Related]  

  • 60. SR 31747. Peripheral sigma receptor antagonist.
    Drugs R D; 1999 Jan; 1(1):108-9. PubMed ID: 10566002
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.